Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$30.82 USD
+0.44 (1.45%)
Updated May 14, 2024 04:00 PM ET
After-Market: $30.83 +0.01 (0.03%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth C Momentum A VGM
Brokerage Reports
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 181 - 200 ( 717 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
4Q20: Laying Groundwork for the Post-COVID Acceleration; Raise Target to $86
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q4/FY20 Financials; Expect EXPAREL® Sales Growth in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Takeaways From Our Coverage at the 2021 H.C. Wainwright BioConnect Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Virtual Fireside Chat with Management Underscores Long- Term Growth Trajectory
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q4 Preview and Highlights from Our Call with Management
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q4 Preview and Highlights from Our Call with Management
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EU Approval Unlocks Potential ~$100M Market Opportunity; Launch in H2:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L